Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Remains a Buy on Inotiv (NOTV)
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating, Announces Target Price $9
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Craig-Hallum Remains a Buy on Inotiv (NOTV)
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Cambodian NHP Suspension Neutral to Positive for Inotiv, Says Lake Street
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Inotiv's Strategic Moves and Financial Outlook Support Buy Rating
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Ascendis Pharma (ASND) and Champions Oncology (CSBR)